ZACKS·2025-09-16 15:46Company Overview - Thermo Fisher Scientific (TMO) launched the Olink Target 48 Neurodegeneration panel, a targeted proteomics immunoassay designed to enhance neurodegenerative disease research by measuring 41 key proteins with absolute quantification from as little as 1µL of plasma sample [1][5][8] - The new panel is part of Olink's expanding portfolio of multiplex disease panels, emphasizing the company's commitment to advancing precision medicine and neurology research [2][3] Product Details - The Target 48 Neurodegeneration panel is designed to meet the increasing demand for scalable and reproducible protein measurements in the context of rising neurodegenerative diseases such as Alzheimer's and Parkinson's [5][9] - It is compatible with the Olink Signature Q100 benchtop system, facilitating a simplified workflow and minimal maintenance, which accelerates biomarker research [6][8] Market Insights - The neurodegenerative disease diagnostics market is projected to grow from $4.70 billion in 2025 at a compound annual growth rate of 7.5% through 2030, driven by the increasing prevalence of neurodegenerative disorders and advancements in diagnostic technologies [10] Financial Performance - Thermo Fisher has a market capitalization of $181.05 billion and an earnings yield of 4.7%, significantly higher than the industry's -4.2% yield [4] - Over the past three months, TMO shares have increased by 21.6%, outperforming the industry growth of 1.9% [12]